Alecensa delivers unprecedented phase III results for people with ALK-positive early-stage lung cancer – Roche
Roche announced that the Phase III ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis…. read more.
